Image Credit: STAT News
STAT+: Novo Holdings is set to close its $16.5 billion acquisition of Catalent after FTC declines to challenge the deal
Catalent is an attractive target because it is a subcontractor that already helps manufacture the Wegovy anti-obesity drug